Drug Trial Radar · NCT05086107
Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment
Last checked: Nov 19, 2026Latest source record: Jan 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Oct 8, 2021
Primary completion
May 30, 2022
Study completion Jan 16, 2023
Sponsor
- Lead sponsor
- BioVersys AGIndustry
- Sponsor type
- Industry
- Collaborators
- Clinical Research Units Hungary
- First posted
- Oct 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To investigate the pharmacokinetics (PK) of rifabutin in subjects with renal impairment after single intravenous (IV) infusion of BV100
Conditions
- Renal Impairment
Interventions
BV100Drug
Rifabutin for infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- To investigate the pharmacokinetics (PK) of rifabutin in subjects with renal impairmentTime frame: 96 hours
- To characterize the single dose pharmacokinetic profile of rifabutinTime frame: 96 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CRU Hungary Kft., Early Phase Unit
Miskolc, Hungary
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.